Japan Society for the Promotion of Science:Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)
Date (from‐to) : 2012/04 -2015/03
Author : SASAKI Hidefumi; YANO Motoki; OKUDA Katsuhiro
Molecular targeted therapies such as erlotinib or gefitinib that target EGFR mutations and crizotinib that target ALK fusion have demonstrated superior single agent activity in selected patients as compared to standard chemotherapy regimes in lung cancer treatment. Recently, a series of new gene fusions have been described in patients with lung cancer using next generation sequencing. In 2012, we have discovered RET translocation in lung adenocarcinomas. In our cohort, three RET fusion mutants were found. We have developed FISH probes to detect RET translocations. in 2013, we have discovered NTRK1 translocation in lung adenocarcinomas. in 2014, we have discovered FGFR3 translocations in lung adenocarcinomas. In addition, BRAF V600E is a driver mutation that can be effectively targeted with selective BRAF inhibitors. To determine the BRAF mutation status in Japanese lung carcinoma, we investigated BRAF V600E mutations by real time-PCR (CAST-PCR) and immunohistochemical methods.